Intratracheal Umbilical Cord-derived Mesenchymal Stem Cells for Severe Bronchopulmonary Dysplasia
- Conditions
- Bronchopulmonary DysplasiaExtremely Premature InfantsSevere BPD That Conventional Therapies Has FailedNo Severe Congenital Anomaliesno Severe IVH Neither Cystic PVL
- Interventions
- Biological: ucMSCsOther: Normal saline
- Registration Number
- NCT01207869
- Lead Sponsor
- China Medical University Hospital
- Brief Summary
Mesenchymal stem cells (MSCs) have been reported to be effective to prevent alveolar growth arrest in experimental bronchopulmonary dysplasia (BPD). The aim is to treat the extremely premature infant with severe BPD to establish whether intratracheal instillation of umbilical cord-derived MSCs (ucMSCs) is safe and effective as a rescue treatment for severe BPD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 10
- severe BPD, defined by the National Institute of Child Health and Human Development workshop, who conventional therapies (including furosemide and theophylline, and HFO ventilation) has failed
- severe congenital anomalies
- severe intraventricular hemorrhage ≥ grade 3 or cystic periventricular leukomalacia.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Mesenchymal stem cells ucMSCs the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube Control Normal saline Normal saline
- Primary Outcome Measures
Name Time Method The relations between the cytokine concentrations in the BAL fluid and PAP. Up to 20 weeks To examine the relations between the cytokine concentrations in the BAL fluid and PAP.
- Secondary Outcome Measures
Name Time Method The severity score of BPD ranging from 0 to 6 on the serial chest radiographs 6 months to 1 year The severity score of BPD ranging from 0 to 6 on the serial chest radiographs will be graded by a single radiologist, without knowledge of the infant's identity or clinical course, using the roentgenographic severity scoring system.
Trial Locations
- Locations (1)
China Medical University Hospital
🇨🇳Taichung,, Taiwan